Bejar Rafael 4

What Happened

• Rafael Bejar, former SVP & Chief Medical Officer of Aptose Biosciences, disposed of a combination of common shares and derivative securities (options/performance options) back to the issuer on 2026-06-30 in connection with a board-, shareholder- and court-approved business arrangement in which Hammi Pharmaceuticals acquired Aptose. The filing shows: 244 common shares sold at US$1.72 each (proceeds $420) and multiple derivative dispositions totaling 1,578,000 shares (reported with $0 in the line items). Footnote clarifies the transaction price was C$2.41 per share (converted at C$1.40 = US$1.00), which implies total consideration of roughly US$2.7 million for all 1,578,244 shares/options combined.

Key Details

• Transaction date: 2026-06-30; Form 4 filed 2026-07-01 (covering the 6/30 transactions).
• Reported prices: C$2.41 per share (F1), converted to US$1.72 per share (F2). The 244 common shares show $1.72/share and $420 total; derivative lines report $0 but are explained by F1/F2.
• Share counts disposed: 244 common shares + 35,000 + 200,000 + 400,000 + 343,000 + 200,000 + 400,000 = 1,578,244 total shares/option-equivalents.
• Approximate total consideration: ~US$2.7M (1,578,244 × ~$1.72) based on the footnoted acquisition price and conversion.
• Shares owned after transaction: not disclosed in the filing.
• Notable footnotes:
  • F1: Dispositions pursuant to Hammi acquisition of all outstanding shares at C$2.41/share.
  • F2: Exchange rate used C$1.40 = US$1.00.
  • F3/F4: Some options subject to vesting schedule and performance criteria.
• Filing timeliness: Form 4 filed the next day (no late-filing flag indicated in the provided data).

Context

• Many lines are “derivative” dispositions (reported with $0) — the filing’s footnotes clarify these were surrendered/transferred to the issuer as part of the company sale, not gifts. That means options and performance stock options were converted/cancelled under the deal rather than representing open-market sales.
• Vesting and performance conditions may have affected how options were treated (see F3 and F4). Also, reported amounts and option counts have been adjusted historically for reverse stock splits (noted in the remarks).
• This is an exit tied to a corporate acquisition rather than a routine open-market sale; it’s informational about deal consideration rather than a standalone insider sentiment trade.